Man Group’s Eterna Therapeutics ERNA Stock Holding History

Man Group’s Portfolio ERNA Stock Details ERNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-6	Closed	-$10K	–	2046
2022 Q3	$10K	Buy	+6	New	+$20.7K	﹤0.01%	1980
2022 Q2	–	Hold	0	–	–	–	2011

Other funds holding ERNA

Naviter Wealth Little Rock, Arkansas $801M AUM 22.2% 1-Year Est. Return

CPWM

Cypress Point Wealth Management Dallas, Texas $492M AUM 22.57% 1-Year Est. Return

Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Man Group's ERNA Position: Q4 2022 in Review

Man Group sold out of Eterna Therapeutics (ERNA) in Q4 2022, closing a stake of 6 shares — an estimated $10K sold.

Man Group first reported a position in ERNA in Q3 2022 and held it in 1 quarter. The position peaked at $10K in Q3 2022. 11 funds tracked by Wall St. Rank hold ERNA as of Q4 2022.

Man Group reported no remaining Eterna Therapeutics position as of Q4 2022 after selling out during the quarter.
Man Group sold 6 Eterna Therapeutics shares in Q4 2022, an estimated $10K.
Man Group first reported a position in Eterna Therapeutics in Q3 2022 and held it in 1 quarter.
Man Group's Eterna Therapeutics position peaked at $10K in Q3 2022.
11 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q4 2022.

Based on Man Group's 13F filing for Q4 2022, filed 14 Feb 2023.